段丽娜, 徐海樱. 利伐沙班对肺栓塞患者的治疗效果及对动脉血氧分压的影响[J]. 实用临床医药杂志, 2020, 24(10): 85-87. DOI: 10.7619/jcmp.202010021
引用本文: 段丽娜, 徐海樱. 利伐沙班对肺栓塞患者的治疗效果及对动脉血氧分压的影响[J]. 实用临床医药杂志, 2020, 24(10): 85-87. DOI: 10.7619/jcmp.202010021
DUAN Lina, XU Haiying. Curative efficacy of rivaroxaban in the treatment of pulmonary embolism and it impact on arterial blood oxygen pressure[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 85-87. DOI: 10.7619/jcmp.202010021
Citation: DUAN Lina, XU Haiying. Curative efficacy of rivaroxaban in the treatment of pulmonary embolism and it impact on arterial blood oxygen pressure[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 85-87. DOI: 10.7619/jcmp.202010021

利伐沙班对肺栓塞患者的治疗效果及对动脉血氧分压的影响

Curative efficacy of rivaroxaban in the treatment of pulmonary embolism and it impact on arterial blood oxygen pressure

  • 摘要: 目的 探讨利伐沙班对肺栓塞患者的治疗效果。 方法 回顾性分析80例肺栓塞患者的临床资料,按不同治疗方案分为2组。40例采用利伐沙班治疗的患者纳入利伐沙班组, 40例采用华法林治疗的患者纳入华法林组,比较2组动脉血氧分压[p(O2)]及出血事件发生率。 结果 利伐沙班组、华法林组治疗总有效率分别为92.50%、87.50%, 差异无统计学意义(P>0.05)。2组治疗后p(O2)较治疗前显著升高,动脉血二氧化碳分压[p(CO2)]较治疗前显著降低(P<0.05)。利伐沙班组出血事件发生率(7.50%)低于华法林组(30.00%), 差异有统计学意义(P<0.05)。 结论 利伐沙班治疗肺栓塞具有显著效果,可改善动脉血氧分压,且无明显出血事件,安全性高。

     

    Abstract: Objective To analyze the curative effect of rivaroxaban for patients with pulmonary embolism. Methods The clinical data of 80 patients with pulmonary embolism admitted in our hospital was retrospectively analyzed, and these patients were divided into two groups according to different treatment schemes. Forty patients treated with rivaroxaban were selected as rivaroxaban group, and another 40 patients treated with warfarin were selected as warfarin group. The arterial oxygen partial pressure[p(O2)] and incidence of bleeding were compared between the two groups. Results The total effective rates of the rivaroxaban group and warfarin group were 92.50%and 87.50%, respectively, and no significant difference was found(P>0.05). The p(O2)increased and partial pressure of carbon dioxide[p(CO2)] decreased after treatment in both groups compared with before treatment(P<0.05). The incidence of bleeding in the rivaroxaban group was 7.50%, which was significantly lower than 30.00%in the warfarin group(P<0.05). Conclusion Rivaroxaban has significant effect on pulmonary embolism. It can improve arterial blood oxygen partial pressure, and has higher safety and no occurrence of bleeding.

     

/

返回文章
返回